Median time to local progression and median time to new bone metastases were advantageously delayed in the P+RT group.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:To analyze the impact of pamidronate (P) use on results of the palliative radiation treatment (RT) of bone metastases, 47 patients with bone metastases were treated with P+RT (19 patients) or RT alone (27 patients).
📊
Temel Bulgular & Veri:RT was delivered with a standard scheme (10x3 Gy). 90 mg monthly-infusions of P, which started from the day of RT and continued up to 9 months, were given in the P+RT group.
💡
Sonuç & Katkı:Median time to local progression and median time to new bone metastases were advantageously delayed in the P+RT group.
To analyze the impact of pamidronate (P) use on results of the palliative radiation treatment (RT) of bone metastases, 47 patients with bone metastases were treated with P+RT (19 patients) or RT alone (27 patients). RT was delivered with a standard scheme (10x3 Gy). 90 mg monthly-infusions of P, which started from the day of RT and continued up to 9 months, were given in the P+RT group. After 24 weeks of follow-up, changes in the pain scores, quality of life index, ALP, tumor marker and Bone Mineral Density levels of whole skeleton significantly improved from base line in the P+RT group compared to RT alone group. Median time to local progression and median time to new bone metastases were advantageously delayed in the P+RT group.
YAVUZ, M. N., YAVUZ, A., KAVGACI, H., İLİS, E., AYDIN, F., ÇAKIRBAY, H. (2002). Effects of pamidronate use on the palliative radiotherapy of bone metastases. Turkish Journal of Cancer, Cilt: 32 - Sayı: 2, 57–65. https://ajindex.com/articles/368367
Hendrickson FR, Shehata WM, Kirchner AB, et al. Radiation therapy for osseous metastasis. Int J Radiat Oncol Biol Phys 1976;1:275-8
Ben-Josef E, Shamsa F, William AO, et al. Radiotherapeutic management of osseous metastases: a survey of current patterns of care. Int J Radiat Oncol Biol Phys 1998;40:915-21
Hoskin PJ, Yarnold JR, Roos DR, et al. Radiotherapy for bone metastases. Clin Oncol (R Coll Radiol) 2001;13:88-90
Kellihan MJ, Mangino PD. Pamidronate. Ann Pharmacother 1992;26:1262-9
Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-44
Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomised, placebo-controlled trial. J Clin Oncol 1999;17:1-9
Purohit OP, Anthony C, Radstone CR, et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994;70:554-8
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998;16:593-602
Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14:2552-9
Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebocontrolled multicenter study. Anticancer Res 1999;19:3383-92
Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6
Thiebaud D, Leyvraz S, von Fliedner V, et al. Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 1991;27:37-41
Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997;6:266-71
Rizzoli R, Forni M, Schaad MA, et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 1996;18:531-7 15. Ratanatharathorn V, Powers W, Moss WT, et al. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1-18